{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:29Z","timestamp":1792785869979,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Science and Technology","award":["2024ZD0542200"],"award-info":[{"award-number":["2024ZD0542200"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273740"],"award-info":[{"award-number":["82273740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103943"],"award-info":[{"award-number":["82103943"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition. Whether and how the plasma proteome underlies the heterogeneous associations between MASLD and subsequent health outcomes remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 42 508 participants from the UK Biobank. Steatosis was defined by the fatty liver index. Individuals' MASLD-related proteomic signature was derived from 2911 plasma proteins. Cox models were used to assess the associations of the proteomic signature with 8 chronic diseases: liver fibrosis, cardiovascular disease (CVD), chronic kidney disease (CKD), chronic respiratory disease (CRD), dementia, depression, anxiety, and cancers. Adjusted survival curves were fitted to compare the cumulative incidence rate of diseases across quantiles of the proteomic signature; we further adjusted for the steatosis degree and cardiometabolic factors to test whether the association was independent of them. Mediation analyses were performed to identify mediating proteins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proteomic signature was significantly associated with liver fibrosis, CVD, CKD, CRD, and depression in the MASLD population, with adjusted hazard ratios ranging from 1.30 to 4.94. Survival curves showed that individuals with the highest proteomic signature had the highest risk for these 5 diseases. These risk differences by signature persisted after adjustment for steatosis degree and cardiometabolic factors, except for depression. Proteins including ADM, ASGR1, and FABP4 were identified as common mediators of the association between MASLD and multiple diseases. Mediators of liver fibrosis showed specificity, with CDHR2 being the key protein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease patients with the same steatosis severity but different proteomic responses may have different risks for future outcomes. Several key proteins may contribute to the progression of MASLD-related diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf103","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T08:03:07Z","timestamp":1747296187000},"page":"691-703","source":"Crossref","is-referenced-by-count":10,"title":["Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases"],"prefix":"10.1093","volume":"192","author":[{"given":"Jialong","family":"Wu","sequence":"first","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonghua","family":"Wu","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yi","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, West China Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ju","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Shi","sequence":"additional","affiliation":[{"name":"Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, Groningen 9747 AG ,","place":["Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Sichuan Center for Disease Control and Prevention Department of Information, , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-7946","authenticated-orcid":false,"given":"Xiong","family":"Xiao","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Guo","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Xu","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5713-3603","authenticated-orcid":false,"given":"Xing","family":"Zhao","sequence":"additional","affiliation":[{"name":"West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu 610041, Sichuan ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"1","key":"2025052807111927500_lvaf103-B1","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"3","key":"2025052807111927500_lvaf103-B2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"2025052807111927500_lvaf103-B3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.medj.2024.07.013","article-title":"Multisystem health comorbidity networks of metabolic dysfunction-associated steatotic liver disease","volume":"5","author":"Jiang","year":"2024","journal-title":"Med"},{"key":"2025052807111927500_lvaf103-B4","doi-asserted-by":"publisher","first-page":"e076388","DOI":"10.1136\/bmj-2023-076388","article-title":"Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study","volume":"384","author":"Kim","year":"2024","journal-title":"BMJ"},{"issue":"4","key":"2025052807111927500_lvaf103-B5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J Hepatol"},{"key":"2025052807111927500_lvaf103-B6","doi-asserted-by":"publisher","first-page":"154955","DOI":"10.1016\/j.metabol.2021.154955","article-title":"Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers","volume":"127","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"2025052807111927500_lvaf103-B7","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111s","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"issue":"10","key":"2025052807111927500_lvaf103-B8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"7","key":"2025052807111927500_lvaf103-B9","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"24","key":"2025052807111927500_lvaf103-B10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3748\/wjg.v25.i24.3009","article-title":"Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease","volume":"25","author":"Mato","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2025052807111927500_lvaf103-B11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1055\/s-0041-1730927","article-title":"Insights into nonalcoholic fatty-liver disease heterogeneity","volume":"41","author":"Arrese","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"7","key":"2025052807111927500_lvaf103-B12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2025052807111927500_lvaf103-B13","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0031-3025(16)39817-8","article-title":"The synthesis and secretion of plasma proteins in the liver","volume":"10","author":"Schreiber","year":"1978","journal-title":"Pathology"},{"issue":"7982","key":"2025052807111927500_lvaf103-B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"7708","key":"2025052807111927500_lvaf103-B15","doi-asserted-by":"publisher","first-page":"73-","DOI":"10.1038\/s41586-018-0175-2","article-title":"Genomic atlas of the human plasma proteome","volume":"558","author":"Sun","year":"2018","journal-title":"Nature"},{"issue":"1","key":"2025052807111927500_lvaf103-B16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/hep.23271","article-title":"Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease","volume":"51","author":"Bell","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"2025052807111927500_lvaf103-B17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","article-title":"A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures","volume":"5","author":"Govaere","year":"2023","journal-title":"Nat Metab."},{"key":"2025052807111927500_lvaf103-B18","doi-asserted-by":"publisher","first-page":"105407","DOI":"10.1016\/j.ebiom.2024.105407","article-title":"Plasma proteomic signatures of liver steatosis and fibrosis in people living with HIV: a cross-sectional study","volume":"109","author":"van Eekeren","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"2025052807111927500_lvaf103-B19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/HEP.0000000000000300","article-title":"Plasma proteomic signature of fatty liver disease: the Rotterdam Study","volume":"78","author":"Abozaid","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2025052807111927500_lvaf103-B20","doi-asserted-by":"publisher","first-page":"e8793","DOI":"10.15252\/msb.20188793","article-title":"Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease","volume":"15","author":"Niu","year":"2019","journal-title":"Mol Syst Biol."},{"issue":"4","key":"2025052807111927500_lvaf103-B21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","article-title":"Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"2025052807111927500_lvaf103-B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","article-title":"ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD","volume":"76","author":"Corey","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"2025052807111927500_lvaf103-B23","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/s41591-024-03039-x","article-title":"Proteomic analysis of cardiorespiratory fitness for prediction of mortality and multisystem disease risks","volume":"30","author":"Perry","year":"2024","journal-title":"Nat Med."},{"issue":"1","key":"2025052807111927500_lvaf103-B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s43016-024-01059-x","article-title":"Proteomic signatures of healthy dietary patterns are associated with lower risks of major chronic diseases and mortality","volume":"6","author":"Zhu","year":"2025","journal-title":"Nat Food."},{"issue":"7","key":"2025052807111927500_lvaf103-B25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jchf.2024.02.017","article-title":"The EAT-Lancet diet index, plasma proteins, and risk of heart failure in a population-based cohort","volume":"12","author":"Zhang","year":"2024","journal-title":"Jacc Heart Fail"},{"issue":"5","key":"2025052807111927500_lvaf103-B26","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"2025052807111927500_lvaf103-B27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3350\/cmh.2024.0145","article-title":"Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: a nationwide cohort study","volume":"30","author":"Jeong","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"2025052807111927500_lvaf103-B28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cac2.12454","article-title":"Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects","volume":"43","author":"Chung","year":"2023","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"2025052807111927500_lvaf103-B29","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.32540","article-title":"Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort","volume":"76","author":"Amadou","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"2025052807111927500_lvaf103-B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"2025052807111927500_lvaf103-B31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-024-02347-3","article-title":"Lifestyle factors and their relative contributions to longitudinal progression of cardio-renal-metabolic multimorbidity: a prospective cohort study","volume":"23","author":"Zhang","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2025052807111927500_lvaf103-B32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/21650799211026980","article-title":"Dietary guidelines for Americans, 2020-2025","volume":"69","author":"Phillips","year":"2021","journal-title":"Workplace Health Saf"},{"issue":"3","key":"2025052807111927500_lvaf103-B33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/bib\/bbr001","article-title":"Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data","volume":"12","author":"Simon","year":"2011","journal-title":"Brief Bioinform"},{"issue":"4","key":"2025052807111927500_lvaf103-B34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025052807111927500_lvaf103-B35","doi-asserted-by":"publisher","first-page":"170347","DOI":"10.1016\/j.peptides.2020.170347","article-title":"Adrenomedullin\u2014current perspective on a peptide hormone with significant therapeutic potential","volume":"131","author":"Fischer","year":"2020","journal-title":"Peptides"},{"issue":"7-8","key":"2025052807111927500_lvaf103-B36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/psc.2953","article-title":"Adrenomedullin\u2014new perspectives of a potent peptide hormone","volume":"23","author":"Sch\u00f6nauer","year":"2017","journal-title":"J Pept Sci"},{"issue":"9","key":"2025052807111927500_lvaf103-B37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/CIRCRESAHA.123.321673","article-title":"Clinical potential of adrenomedullin signaling in the cardiovascular system","volume":"132","author":"B\u00e1lint","year":"2023","journal-title":"Circ Res"},{"issue":"1","key":"2025052807111927500_lvaf103-B38","doi-asserted-by":"publisher","first-page":"e2021162","DOI":"10.1084\/jem.20211628","article-title":"Suppression of CCL2 angiocrine function by adrenomedullin promotes tumor growth","volume":"220","author":"Nakayama","year":"2023","journal-title":"J Exp Med."},{"issue":"5","key":"2025052807111927500_lvaf103-B39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.13116","article-title":"Use of proteomics to identify biomarkers associated with chronic kidney disease and long-term outcomes in patients with myocardial infarction","volume":"288","author":"Edfors","year":"2020","journal-title":"J Intern Med"},{"issue":"11","key":"2025052807111927500_lvaf103-B40","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0196-9781(01)00513-7","article-title":"A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides","volume":"22","author":"Eto","year":"2001","journal-title":"Peptides"},{"key":"2025052807111927500_lvaf103-B41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pnpbp.2013.07.003","article-title":"Possible role of adrenomedullin and nitric oxide in major depression","volume":"46","author":"Akpinar","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"14","key":"2025052807111927500_lvaf103-B42","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.3390\/ijms21144818","article-title":"ASGR1 and its enigmatic relative, CLEC10A","volume":"21","author":"Hoober","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"7922","key":"2025052807111927500_lvaf103-B43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-022-05006-3","article-title":"Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"2025052807111927500_lvaf103-B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2020.07.001","article-title":"Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects","volume":"306","author":"Ali","year":"2020","journal-title":"Atherosclerosis"},{"issue":"8","key":"2025052807111927500_lvaf103-B45","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/s42255-022-00623-8","article-title":"Targeting ASGR1 to lower cholesterol","volume":"4","author":"Rader","year":"2022","journal-title":"Nat Metab."},{"issue":"10","key":"2025052807111927500_lvaf103-B46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2015.122","article-title":"Metabolic functions of FABPs\u2014mechanisms and therapeutic implications","volume":"11","author":"Hotamisligil","year":"2015","journal-title":"Nat Rev Endocrinol."},{"issue":"26","key":"2025052807111927500_lvaf103-B47","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/eurheartj\/ehz856","article-title":"Adipocytes promote interleukin-18 binding to its receptors during abdominal aortic aneurysm formation in mice","volume":"41","author":"Liu","year":"2020","journal-title":"Eur Heart J"},{"key":"2025052807111927500_lvaf103-B48","doi-asserted-by":"publisher","first-page":"155528","DOI":"10.1016\/j.metabol.2023.155528","article-title":"Targeting FABP4 in elderly mice rejuvenates liver metabolism and ameliorates aging-associated metabolic disorders","volume":"142","author":"Lv","year":"2023","journal-title":"Metabolism"},{"issue":"9","key":"2025052807111927500_lvaf103-B49","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1111\/jcmm.14512","article-title":"Pharmacological and genetic inhibition of fatty acid-binding protein 4 alleviated cisplatin-induced acute kidney injury","volume":"23","author":"Tan","year":"2019","journal-title":"J Cell Mol Med."},{"issue":"12","key":"2025052807111927500_lvaf103-B50","doi-asserted-by":"publisher","first-page":"e3001463","DOI":"10.1371\/journal.pbio.3001463","article-title":"Heterophilic and homophilic cadherin interactions in intestinal intermicrovillar links are species dependent","volume":"19","author":"Gray","year":"2021","journal-title":"PLoS Biol."},{"issue":"1","key":"2025052807111927500_lvaf103-B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1535370215597194","article-title":"Epithelial-mesenchymal transition: an emerging target in tissue fibrosis","volume":"241","author":"Li","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"2025052807111927500_lvaf103-B52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/oby.23598","article-title":"FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation","volume":"31","author":"Li","year":"2023","journal-title":"Obesity"},{"key":"2025052807111927500_lvaf103-B53","doi-asserted-by":"publisher","first-page":"364209","DOI":"10.1155\/2014\/364209","article-title":"Obesity and low-grade inflammation increase plasma follistatin-like 3 in humans","volume":"2014","author":"Brandt","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"10","key":"2025052807111927500_lvaf103-B54","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/ndt\/gfw472","article-title":"FSTL3 is increased in renal dysfunction","volume":"32","author":"Kralisch","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"1-2","key":"2025052807111927500_lvaf103-B55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cca.2008.10.003","article-title":"Carboxypeptidase M: multiple alliances and unknown partners","volume":"399","author":"Deiteren","year":"2009","journal-title":"Clin Chim Acta"},{"key":"2025052807111927500_lvaf103-B56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/0-306-46826-3_23","volume-title":"Cellular Peptidases in Immune Functions and Diseases 2","author":"Rehli","year":"2002"},{"issue":"12","key":"2025052807111927500_lvaf103-B57","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1038\/s41380-021-01188-w","article-title":"Association of inflammation with depression and anxiety: evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts","volume":"26","author":"Milaneschi","year":"2021","journal-title":"Mol Psychiatry."},{"issue":"6","key":"2025052807111927500_lvaf103-B58","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/mp.2008.131","article-title":"Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts","volume":"15","author":"Muglia","year":"2010","journal-title":"Mol Psychiatry."},{"issue":"9","key":"2025052807111927500_lvaf103-B59","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cgh.2012.12.031","article-title":"External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study","volume":"11","author":"Koehler","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"22","key":"2025052807111927500_lvaf103-B60","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1097\/CM9.0000000000000503","article-title":"Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome","volume":"132","author":"Chen","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"2025052807111927500_lvaf103-B61","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1111\/liv.12305","article-title":"How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound","volume":"34","author":"Carvalhana","year":"2014","journal-title":"Liver Int"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf103\/63212489\/lvaf103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/5\/691\/63212489\/lvaf103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/5\/691\/63212489\/lvaf103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:11:23Z","timestamp":1748416283000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/192\/5\/691\/8133932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf103","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,30]]}}}